Overdiagnosis in Lung Cancer Screening: Still the Unavoidable Cost of Doing Business?
Lung cancer (LC) remains one of the most formidable challenges in public health and claims more lives globally than any other form of cancer.1 Late diagnosis plays a pivotal role in determining its dismal survival rates. In an effort to improve outcomes, LC screening (LCS) programs that are based on low-dose computed-tomography (LDCT) scanning have been introduced.2 The rationale is clear: early detection could lead to early intervention, potentially reducing mortality rates.3
Authors
- Luigi Rolli (ORCID: https://orcid.org/0000-0002-6673-5785)
- Ugo Pastorino (ORCID: https://orcid.org/0000-0001-9974-7902)
- Riccardo Orlandi (ORCID: https://orcid.org/0000-0002-4113-1598)
Institutions
- University of Milan (IT)
- Tumori Foundation (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Annals of Thoracic Surgery Short Reports
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1016/j.atssr.2025.01.002
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00